Formal guidelines play an important role in disseminating the best available evidence knowledge and are expected to provide simple and practical recommendations for the most optimal management of patients with various conditions. Such guidelines have important implications for many disease states, which thereby could be more professionally managed in everyday clinical practice by clinicians with divergent educational backgrounds, and also more easily implemented in wards or outpatient clinics eliminating inequalities in health care management.
Introduction
Prevention of stroke is central to the optimal management of patients with atrial fibrillation (AF). Oral anticoagulant therapy (OAC) using well-controlled vitamin K antagonists (VKAs) or non-VKA oral anticoagulants(NOACs) effectively reduces stroke and all-cause mortality in atrial fibrillation patients, but the treatment benefit must be balanced against the risk of OAC-related major bleeding. Worldwide, the VKAs remain the most widely used OAC, although the NOACs use is increasing rapidly . In 2014, guidelines from the AHA/ACC/HRS and National Institute for Health and Care Excellence (NICE) were published 3, 4 , while in 2016, a focussed update from the Canadian Cardiovascular Society (CCS) 5 and new
European Society of Cardiology (ESC) guidelines 6 were published. The last Asia-Pacific Heart Rhythm Society 7 and American College of Chest Physicians (ACCP) 8 guidelines on antithrombotic therapy in atrial fibrillation were published in 2012-2013, and new versions are pending.
In this brief Viewpoint, we provide an appraisal of the recommendations pertinent to the prevention of atrial fibrillation -related stroke or systemic thromboembolism, as provided in more recently published guidelines for the management of patients with atrial fibrillation.
Stroke and bleeding risk assessment
Most of the contemporary international guidelines on atrial fibrillation management published since 2013 recommend the CHA 2 DS 2 -VASc score for stroke risk assessment in atrial fibrillation. The CHA 2 DS 2 -VASc score, which has been validated in numerous different atrial fibrillation cohorts, provides a good balance of predictive ability and practicality and has often outperformed other stroke risk assessment tools in the reliable identification of 'truly low risk'
patients, who need no antithrombotic therapy due to low annual stroke rates of <1% 10, 11 . Like many clinical factor-based risk scores in the atrial fibrillation or non-atrial fibrillation setting, CHA 2 DS 2 -VASc only has a modest predictive value for identifying the 'high risk' patients who subsequently develop events. As would be expected, for each point of the CHA 2 DS 2 -VASc score there would be a wide range of reported event rates, given that this would be dependent on population studied (trial vs 'real-world'), clinical setting (hospitalised vs community cohorts), ethnicity, etc 12, 13 .
The predictive value of clinical risk scores can always be improved by the addition of biomarkers ('biological markers', whether blood, urine or imaging based). In the light of recent sub-studies from the landmark NOAC trials (describing the role of various blood biomarkers in the prediction of stroke, bleeding or death in anticoagulated patients) [14] [15] [16] , the 2016 ESC Guidelines recommend that 'biomarkers such as high-sensitive troponin or natriuretic peptide may be considered to further refine stroke and bleeding risk' (Class IIb, Level B). This is a weak recommendation for a number of reasons. First, these findings were derived mostly from the already anticoagulated cohorts, and it is unclear whether they could be extrapolated to nonanticoagulated patients, a substantially different population which includes many lower-risk patients for whom the decision to use an OAC is yet to be made. Second, a large body of evidence shows the association of various biomarkers of thrombogenesis, inflammation, myocardial damage, impaired cardiac function, oxidative stress, renal failure, etc. (e.g., von
Willebrand factor, D-dimer, C-reactive protein, cardiac troponins, glomerular filtration rate, etc.) with increased risk of stroke in atrial fibrillation patients, and it is not clear why highsensitive troponin or natriuretic peptide should be preferred 17 . The particular biomarker cut-off values relevant for stroke or bleeding risk evaluation are unknown, notwithstanding the inter-
assay variability in measuring the biomarker levels, cost issues and patient variability (some have a diurnal pattern and can be influenced by co-morbidities such as renal impairment).
Many of these biomarkers not only predict stroke or bleeding, but death, myocardial infarction and heart failure -and may confuse clinicians who may try to balance the various outcomes.
Finally, the use of biomarkers needs to be tempered by cost, as well as loss of simplicity and practicality for everyday use.
The introduction of biomarkers to refine stroke risk stratification, albeit statistically improving on clinical scores, may result in delayed or postponed OAC initiation while waiting for test results with the risks inherent to the treatment omission. Nevertheless, the new recommendation to consider biomarkers for stroke and bleeding risk assessment indicates future development possibilities for improved risk prediction, especially for those at the 'borderline' threshold for OAC.
OAC-related bleeding risk
The assessment of OAC-related bleeding risk is not a new concept but has been subject to considerable misuse and misinterpretation 18 . The 2016 ESC Guidelines provide guidance to practitioners, but focus on listing the modifiable, partly modifiable, non-modifiable and biomarker-related bleeding risk factors, rather than recommending a specific bleeding risk score, of which there are now many [19] [20] [21] [22] [23] , including the HAS-BLED score which was recommended in earlier ESC guidelines 9 19 . The modifiable bleeding risk factors, to which our attention is drawn are all factors listed in the HAS-BLED score.
The HAS-BLED score 19 has been well-validated in various atrial fibrillation cohorts, including patients treated with NOACs or a combination of OAC and antiplatelet drugs. The HAS-BLED score enables a simple identification of increased bleeding risk (i.e., score ≥3 points) and 'flags up' the patient potentially at risk of bleeding for more careful review and follow-up.
Importantly, HAS-BLED draws attention to the reversible bleeding risk factors (summarised in 
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. The outline of bleeding risk factors in the new guidelines is very useful but could easily have been added to the more common bleeding risk assessment using the HAS-BLED score. Indeed, the new guidelines recommend that bleeding risk scores should be considered in atrial fibrillation patients on OAC to identify modifiable risk factors for major bleeding (Class IIa, Level B), but do not refer to a specific bleeding risk score, which may confuse clinicians.
Nevertheless, we welcome the 2016 ESC Guidelines note that 'a high bleeding risk score should generally not result in withholding OAC.'. This may be particularly important in atrial fibrillation patients with an acute coronary syndrome or percutaneous coronary intervention, in whom the choice of optimal treatment regimen (i.e., a combination of OAC and antiplatelet therapy for a variable time period) highly depends on the estimated thrombotic and bleeding risks.
Bleeding management whilst on OAC is highlighted in the new ESC guidelines, especially since we are entering an era of reversal agents and specific antidotes to the NOACs, with idarucizumab already being available for dabigatran 26 .
Stroke prevention strategies
The new 2016 ESC Guidelines fully acknowledge that aspirin has no role in the prevention of atrial fibrillation-related stroke or systemic thromboembolism 27 (Class III recommendation). To inform decision-making pertinent to atrial fibrillation patients with a single additional stroke risk factor, the 2016 ESC Guideline Task Force commendably commissioned a systematic review of observational studies reporting the annual stroke rates in such non-anticoagulated patients 28 . The stroke rates in those studies were highly heterogeneous and sometimes low 10, 12, 13, 29 . A recent meta-analysis 30 found that the annual stroke risk in the CHA 2 DS 2 -VASc score 1 category is sufficiently high to prescribe a NOAC but not warfarin; however, the CHA 2 DS 2 -VASc score 1 data in the meta-analysis included low-risk females with score 1 who should not receive antithrombotic therapy, while the treatment threshold for well-managed warfarin with highquality anticoagulation control would probably approach that of NOACs 31 . . An ancillary analysis from the SPORTIF trials showed that high time in therapeutic range (TTR) amongst warfarin users was associated with low event rates, suggesting that the treatment threshold for warfarin could be comparable to that seen for NOACs 31 .
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With a single stroke risk factor, it is only common sense that not all risk factors carry equal weight, and reported event rates would differ by study setting, population and ethnicity. The most robust study (not considered by the guidelines) 10, 29 , larger than other European atrial fibrillation cohorts altogether (n=177,966), reported event rates according to the selected outcome criteria and specific CHA 2 DS 2 -VASc score levels 36 , showing how stroke rates vary with different methodological approaches, especially in patients with a single additional stroke risk factor.
Methodological differences in the definition of cohorts 'off OAC treatment' would significantly influence the reported stroke rates, most relevant to a CHA 2 DS 2 -VASc score of 0 and 1. For example, two Swedish studies 37 38 cited in the guidelines reported that patients with a CHA 2 DS 2 -VASc score of 1 would not benefit from OAC, but these studies excluded all patients who during follow-up had initiated OAC treatment, thus 'conditioning on the future' and biasing outcomes towards lower event rates by excluding the higher-risk subjects who would have been started on OAC during follow-up.
Simple stroke risk scores such as CHA 2 DS 2 -VASc are designed to be reductionist, and help dichotomise (and simplify) decision-making. Thus, once the individual stroke risk has been established to be above the threshold for OAC use, what difference would it make if the score M A N U S C R I P T
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10 was 2 or 9, or the patient's risk was 2 or7% per year? OAC should be the default treatment at any stroke risk level exceeding the treatment threshold, excluding 'truly low-risk' AF patients (see the Birmingham '3-step' algorithm, Figure 1 ).
This simplified concept of considering OAC use in all atrial fibrillation patients with ≥1 additional stroke risk factors (excluding female sex as the only risk factor) leads to improved adherence to guidelines with better outcomes in daily practice and is cost-effective 4, 39 . Modelling analyses show that adoption of the CHA 2 DS 2 -VASc-based approach and NOAC use would result in an annual reduction of >60000 strokes, deaths and bleeding events in Europe alone 40 .
Hence, patients with atrial fibrillation and a single additional stroke risk factor should generally not be denied OAC on the grounds of a misperception that their risk of stroke is insufficiently high to justify OAC use. In comparison to no therapy or aspirin, the use of OAC (well-controlled VKA or NOACs) in such patients has been associated with a positive net clinical benefit, with significant reduction in stroke, systemic embolism or death and no increase in major bleeding relative to aspirin 41, 42 .
Choosing between NOACs and VKAs in daily practice
Compared to VKAs, NOACs have the advantage of greater safety (significantly lower risk of haemorrhagic stroke or other intracranial haemorrhage, critical site or life-threatening/fatal bleeding) and more convenient use (fixed dosing without the need for routine laboratory control of anticoagulation intensity, but requiring strict adherence to treatment), and are at least as effective as VKAs in stroke prevention in atrial fibrillation patients.
However, VKAs are still widely used for the prevention of atrial fibrillation -related stroke, mostly due to the cost and reimbursement issues, and for patients whose adherence to therapy is uncertain. The quality of the management of VKA therapy has generally improved, particularly in Europe. 
